Regulatory
Retatrutide approval – status 2026
Retatrutide (LY3437943) is still in the regulatory approval phase as a commercial finished medicine, but is accessible through approved clinical study programs such as our partner clinic's. The compound is in Phase III (TRIUMPH program). Overview of the current status at FDA, EMA and in Germany.
FDA (USA)
Review process ongoing within Phase III trials. No regulatory submission before 2026.
EMA (EU)
EMA to date lists Retatrutide only in the context of a pediatric investigation plan. Obesity approval follows the FDA decision.
Germany (BfArM)
No finished pharmaceutical on the market. Prescription is possible within approved clinical studies.
- 2022
Phase II data published
NEJM: up to 24% weight loss after 48 weeks at 12 mg weekly.
- 2023
TRIUMPH Phase III program starts
TRIUMPH-1 through TRIUMPH-4 enroll tens of thousands of participants worldwide.
- 2025
First Phase III readouts
Interim analyses confirm efficacy and safety profile.
- 2026
Expected regulatory submission
Eli Lilly plans submission to FDA and EMA after completion of TRIUMPH-1.
- 2027
Possible market approval
Earliest realistic timing for regular approval in the US and EU.
TRIUMPH-1 – the pivotal trial
TRIUMPH-1 is the pivotal Phase III registration trial: approximately 2,100 adults with obesity, 80-week treatment duration, versus placebo. Trial completion provides the data basis for the FDA and EMA submission.
Note: All approval dates are projections based on current Eli Lilly communication and trial registrations. Delays are possible.
Treatment available
Request a personal consultation
We offer this treatment – free initial consultation.